Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Maravai Lifesciences Holdings (MRVI)
NASDAQ:MRVI
RESEARCH TOOLSreports
Holding MRVI?
Track your performance easily
Earnings Data
Report Date
Feb 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.04Last Year’s EPS
$0.01Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -30.74%
|Next Earnings Date:Feb 19, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with notable achievements in innovation and strategic acquisitions, but faced challenges in revenue shortfalls, market softness, and a significant goodwill impairment charge. The company's strong cash position and commitment to innovation are positive, but the financial pressures and revised guidance indicate ongoing challenges.Company Guidance
In the Maravai LifeSciences third quarter 2024 earnings call, guidance provided included an updated revenue outlook for the year, now expected to be between $255 million and $265 million, reflecting a reduction due to softer CleanCap demand and customer delays. The Nucleic Acid Production (NAP) segment is projected to generate between $193 million and $202 million, while the Biologics Safety Testing (BST) segment is anticipated to bring in $62 million to $63 million. Adjusted EBITDA margin guidance has been revised to 16% to 18% due to lower anticipated revenues and a shift in customer GMP programs to 2025. The company reported $65 million in Q3 revenue, $13 million in adjusted EBITDA, a loss of $0.02 in adjusted EPS, and a net cash position of nearly $50 million. The call highlighted ongoing strategic investments, including the acquisition of Officinae Bio, expected to enhance Maravai's mRNA capabilities.mRNA Clinical Trial Growth
The non-COVID mRNA trials have steadily increased each year and are up 29% year-to-date through Q3. Clinical trials initiated for guide RNA-mediated gene editing are up 75% year-to-date through Q3.
Innovation and Product Launches
Introduced 21 new products year-to-date in the NAP business segment. Launched CleanScribe RNA Polymerase, reducing double-stranded RNA by up to 85%, and received positive feedback from top pharma customers.
Officinae Bio Acquisition
Signed a definitive agreement to acquire the DNA and RNA businesses of Officinae Bio, enhancing mRNA offering for early phase discovery work with AI-driven digital platform.
Strong Financial Position
Ended Q3 with $578 million in cash and a net cash position of nearly $50 million, providing strategic flexibility.
---
MRVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MRVI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $7.84 | $5.08 | -35.20% |
| Aug 07, 2024 | $9.10 | $8.48 | -6.81% |
| May 08, 2024 | $8.87 | $9.86 | +11.16% |
| Feb 22, 2024 | $5.11 | $8.36 | +63.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Maravai Lifesciences Holdings (MRVI) report earnings?
Maravai Lifesciences Holdings (MRVI) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
What is Maravai Lifesciences Holdings (MRVI) earnings time?
Maravai Lifesciences Holdings (MRVI) earnings time is at Feb 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MRVI EPS forecast?
MRVI EPS forecast for the fiscal quarter 2024 (Q4) is -$0.04.
---